Actinogen FY22 Results - Accelerating Clinical Development
Filed with ASX · · 4 pages · English
Sydney, 25 August 2022. Actinogen Medical ASX: ACW (“ACW” or “the Company”)is pleased to release its results and annual report for the year ended 30 June 2022. Key Highlights ® Accelerating the Xanamem clinical development program with a focus on cognition • Reported strongly positive results for attention and working memory (cognition) in the XanaMIA Part A trial • Initiated strategic adjustments
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW Appendix 4E and 2022 Annual Report
- ACW CEO presentation to Spark Plus Aust Equities Day
- Application for quotation of securities - ACW
- ACW announces Phase 2 trial designs for AD & MDD
- Actinogen trial results & strategic update presentation
Later from Actinogen Medical
- ACW announces positive Alzheimers Disease clinical results
- ACW clinical biomarker study webcast presentation
- R&D tax incentive rebate received
- First patient treated in XanaCIDD Phase 2 Depression Trial
- FDA agrees to six-month Phase 2b Alzheimers Disease Trial
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical